Fasudil does not improve lab tests in Raynaud's phenomenon
from Reuters via Medscape
The Rho-kinase inhibitor fasudil does not improve laboratory measures associated with Raynaud's phenomenon secondary to systemic sclerosis, a new study shows. Fasudil is used in Japan to treat vasospasm, and the Rho/Rho-kinase signaling pathway is important in cold-induced vasospasm, which is why the researchers had hoped the drug would help in this setting.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063